Trials / Recruiting
RecruitingNCT07271667
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- Sponsor
- Curis, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emavusertib | Oral tablets |
| DRUG | Zanubrutinib | Oral capsules |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2027-11-01
- Completion
- 2027-11-01
- First posted
- 2025-12-09
- Last updated
- 2026-03-30
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07271667. Inclusion in this directory is not an endorsement.